Organon pharmaceuticals steroids

On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital's Alexander J. Denner, . to a two-year term on the company's Board of Directors. Previously, Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad's second-largest shareholder. On January 10, 2016, Ariad announced that Denner had become the chairman of the board, replacing Harvey Berger. [9] Shortly thereafter, the company announced the termination of its shareholder's rights plan (the "poison pill.") [10]

Organon pharmaceuticals steroids

organon pharmaceuticals steroids

Media:

organon pharmaceuticals steroidsorganon pharmaceuticals steroidsorganon pharmaceuticals steroidsorganon pharmaceuticals steroidsorganon pharmaceuticals steroids